These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38500864)

  • 61. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
    Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Intraindividual Comparison of
    Kesch C; Vinsensia M; Radtke JP; Schlemmer HP; Heller M; Ellert E; Holland-Letz T; Duensing S; Grabe N; Afshar-Oromieh A; Wieczorek K; Schäfer M; Neels OC; Cardinale J; Kratochwil C; Hohenfellner M; Kopka K; Haberkorn U; Hadaschik BA; Giesel FL
    J Nucl Med; 2017 Nov; 58(11):1805-1810. PubMed ID: 28473595
    [No Abstract]   [Full Text] [Related]  

  • 64. Development and Internal Validation of a Novel Nomogram Predicting the Outcome of Salvage Radiation Therapy for Biochemical Recurrence after Radical Prostatectomy in Patients without Metastases on Restaging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography.
    Meijer D; van Leeuwen PJ; Eppinga WSC; Vanneste BGL; Meijnen P; Daniels LA; van den Bergh RCN; Lont AP; Bodar YJL; Ettema RH; de Bie KCC; Oudshoorn FHK; Nieuwenhuijzen JA; van der Poel HG; Donswijk ML; Heymans MW; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Open Sci; 2024 Mar; 61():37-43. PubMed ID: 38384437
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
    BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
    [TBL] [Abstract][Full Text] [Related]  

  • 66.
    Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
    J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
    Rajwa P; Pfister D; Rieger C; Heidenreich J; Drzezga A; Persigehl T; Shariat SF; Heidenreich A
    Prostate; 2023 Mar; 83(4):385-391. PubMed ID: 36564936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
    Rajwa P; Robesti D; Chaloupka M; Zattoni F; Giesen A; Huebner NA; Krzywon A; Miszczyk M; Moll M; Stando R; Cisero E; Semko S; Checcucci E; Devos G; Apfelbeck M; Gatti C; Marra G; van den Bergh RCN; Goldner G; Rasul S; Ceci F; Dal Moro F; Porpiglia F; Gontero P; Bjartell A; Stief C; Heidenreich A; Joniau S; Briganti A; Shariat SF; Gandaglia G;
    Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37845121
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D; Eppinga WSC; Mohede RM; Vanneste BGL; Meijnen P; Meijer OWM; Daniels LA; van den Bergh RCN; Lont AP; Ettema RH; Oudshoorn FHK; van Leeuwen PJ; van der Poel HG; Donswijk ML; Oprea-Lager DE; Schaake EE; Vis AN
    Eur Urol Oncol; 2022 Apr; 5(2):146-152. PubMed ID: 35074282
    [TBL] [Abstract][Full Text] [Related]  

  • 70.
    Yılmaz B; Şahin S; Ergül N; Çolakoğlu Y; Baytekin HF; Sökmen D; Tuğcu V; Taşçı Aİ; Çermik TF
    Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits.
    Zhu Y; Fan L; Zhu H; Gong Y; Chi C; Wang Y; Pan J; Dong B; Xue W
    Front Oncol; 2023; 13():963411. PubMed ID: 37265786
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improved oncological outcome after radical prostatectomy in patients staged with
    Ferraro DA; Lehner F; Becker AS; Kranzbühler B; Kudura K; Mebert I; Messerli M; Hermanns T; Eberli D; Burger IA
    Eur J Nucl Med Mol Imaging; 2021 Apr; 48(4):1219-1228. PubMed ID: 33074376
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
    Tafuri A; Cerruto MA; Antonelli A
    Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Can
    Yin H; Chen M; Qiu X; Qiu L; Gao J; Li D; Fu Y; Huang H; Guo S; Zhang Q; Ai S; Wang F; Guo H
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.
    Thalgott M; Rack B; Horn T; Heck MM; Eiber M; Kübler H; Retz M; Gschwend JE; Andergassen U; Nawroth R
    Anticancer Res; 2015 Oct; 35(10):5679-85. PubMed ID: 26408743
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
    Devos G; Devlies W; De Meerleer G; Baldewijns M; Gevaert T; Moris L; Milonas D; Van Poppel H; Berghen C; Everaerts W; Claessens F; Joniau S
    Nat Rev Urol; 2021 Dec; 18(12):739-762. PubMed ID: 34526701
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [
    Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
    Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictors of PSMA PET Positivity: Analysis in a Selected Cohort of Biochemical Recurrence Prostate Cancer Patients after Radical Prostatectomy.
    Mapelli P; Ghezzo S; Pini C; Samanes Gajate AM; Spataro A; Bezzi C; Landoni C; Scifo P; Briganti A; Chiti A; Picchio M
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760557
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.